Skip to main content

Drug Interactions between methylnaltrexone and momelotinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

methylnaltrexone momelotinib

Applies to: methylnaltrexone and momelotinib

MONITOR: Coadministration of momelotinib may increase the plasma concentrations of substrates of the organic cation 1 (OCT1) or multidrug toxin extrusion 1 (MATE1) transporters. Based on in vitro data, at clinically relevant concentrations, momelotinib is an inhibitor of OCT1 and its active metabolite, M21, may inhibit MATE1. However, clinical data are not available.

MANAGEMENT: Caution is advised if momelotinib is administered with sensitive substrates of OCT1 and/or MATE1. Patients should be monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever momelotinib is added to or withdrawn from therapy with these drugs. Individual product labeling for the coadministered drug may also be consulted for specific guidance.

References (2)
  1. (2024) "Product Information. Omjjara (momelotinib)." GlaxoSmithKline Australia Pty Ltd
  2. (2025) "Product Information. Omjjara (momelotinib)." GlaxoSmithKline UK Ltd

Drug and food/lifestyle interactions

Moderate

methylnaltrexone food/lifestyle

Applies to: methylnaltrexone

ADJUST DOSING INTERVAL: Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration. When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.

MANAGEMENT: Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.

References (1)
  1. (2008) "Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer